China’s National Health and Family Planning Commission announced the final list of the first series of the national health insurance negotiation, while the oral targeted drug Erlotinib (Tarceva), which used for the non-small cell carcinoma treat, of Roche is not on this list. Actually, it is revealed that Roche has withdrawn from the negotiation early before.

There are three kind of drugs for the terminal stage of non-small cell carcinoma out of the five drugs that has been listed in the negotiation. Accept Erlotinib (Tarceva) of Roche, Gefitinib (Iressa) of Astra Zeneca and Icotinib (Kai Meina) of  Betta Pharmaceuticals are biding for the same entity, while the price pressure is obviously high. And in terms of the final negotiation price that National Health and Family Planning Commission announced, Gefitinib (Iressa) and Icotinib (Kai Meina) decreased 55% and 54% separately, the monthly charge down to 7000 RMB and 5500 RMB respectively.

Replied about the failure, Roche states that, the company has participated in the  negotiation actively, and received the official approvals from some of the related departments, this results will not influence the use of Erlotinib (Tarceva) for all the patients.

This national negotiation aims to bargain through the way and extent that are acceptable for the companies themselves. However, exchange one undetermined market by dwindle down the price is more than considering the problem of whether Chinese market can accept, but also includes how the headquarter measures. Therefore, no matter actively or passive withdraw from the negotiation, Roche is possibly going to face the result that the original tripod marketing division has been destroyed.